You have Javascript disabled. Some elements of this page may not work as expected.
Drugs group Shire generates almost half of its revenues from the attention deficit disorder treatment Adderall. Founded in 1986 the group became a listed company in 1996. Recently acquired TKT in the US and signed a collaboration deal with New River.
Div Yield
0.6%
0.6%
Div Cover
1.8
10.7
Op Mrgn
5.0%
24.7%
ROCE
24.9%
P/E
100.8
15.3
PEG
0.3
0.0
Pr/Revenue
3.5
3.0
Pr/Book
1.7
Revenue
35.6%
16.6%
PBT
-75.8%
2133.1%
EPS
393.5%
564.5%
DPS
20.1%
9.2%
31-Dec-03
1,211.57
406.35
55.40¢
17.1
n/a
n/a
n/a
0.0%
31-Dec-04
1,363.21
459.89
67.20¢
14.2
0.7
+21%
5.67¢
0.6%
31-Dec-05
1,599.30
(143.80)
(36.40)¢
n/a
n/a
n/a
6.24¢
0.5%
31-Dec-06
1,796.50
129.60
3.10¢
596.7
n/a
n/a
7.18¢
0.4%
31-Dec-07
2,436.30
31.40
15.30¢
131.2
0.3
+394%
8.62¢
0.4%
a. Based on UK GAAP presentation of accounts - includes discontinued activities
31-Dec-08
1,626.00 401.54
57.49p
15.3
0.0
+564%
5.39p
0.6%
31-Dec-09
1,581.57 362.63
52.05p
16.9
n/a
-10%
5.97p
0.7%
30-Sep-08
Buy
David Mott
887.56p 15,000
£133,133.60
11-Sep-08
Buy
David Mott
910.13p 15,000
£136,519.55
06-Aug-08
Buy
Graham Hetherington
896.20p 4,000
£35,848.00
Currency
UK Pounds
Share Price
879.00p
Change Today
+28.50p
52 Week High
1,241.00
52 Week Low
745.00
Volume
3,726,202
Shares Issued
560.02m
Market Cap
£4,922.60m
Beta
0.62
RiskGrade
156
Strong Buy
9
Buy
8
Neutral
7
Sell
2
Strong Sell
1
Total
27
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.
Interim
Final
Ex-Div
10-Sep-08
12-Mar-08
Paid
09-Oct-08
09-Apr-08
Amount
2.15¢
6.47¢
16:05
20,100 @ 852.15p
17:07
300 @ 874.00p
16:35
323,882 @ 879.00p
16:29
1,529 @ 880.50p
16:29
142 @ 880.50p
CEO
Angus Russell
CFO
Graham Hetherington
Please wait, loading...